ความสำเร็จในการรับประทานยาสูตร 3HP (Isoniazid+ Rifapentine) ในการรักษาผู้ป่วยวัณโรคระยะแฝง ของบุคลากรทางการแพทย์ประจำอำเภอบรบือ

Abstract

Abstract

            This cross-sectional research aimed to examine the success of taking 3HP latent tuberculosis medication among medical personnel at Borabu hospital and subdistrict health promotion hospitals in Borabu district, conducted from September 2024 to February 2025. A total of 439 cases were included. The majority of the participants were female (324 cases, 73.8%), and most were over 40 years old (140 cases, 31.9%). Medical personnel who consented to undergo screening for latent tuberculosis using the Interferon-Gamma Release Assay (IGRA) were found to have positive IGRA results in 39 cases (8.9%).

            Of the 39 medical personnel with positive IGRA results, 30 cases (76.9%) consented to receive the 3HP regimen. The study found no statistically significant differences in gender or age group (P > 0.05). However, there was a statistically significant association between the institution of employment and latent tuberculosis infection (P < 0.05).
            Among the 30 participants who received the 3HP regimen, 28 (93.3%) completed the treatment, while 2 (6.7%) discontinued due to adverse effects—fever in one case and rash in another. During the 12-week treatment period, 12 participants (40%) experienced adverse reactions, with some reporting more than one symptom. The most common side effects were fatigue and nausea (10 cases, 33.3%), followed by fever, headache, and body aches (9 cases, 30%), rash (6 cases, 20%), numbness in the hands and feet (3 cases, 10%), and diarrhea (1 case, 3.3%). No cases of hepatitis or other severe side effects were reported. Most adverse reactions occurred during the first month of treatment and were self-limiting.

Keywords : latent tuberculosis, 3HP Latent Tuberculosis Drug, Adverse drug reaction